In last trading session, Relmada Therapeutics Inc (NASDAQ:RLMD) saw 1.28 million shares changing hands with its beta currently measuring 0.62. Company’s recent per share price level of $0.67 trading at $0.13 or 25.53% at ring of the bell on the day assigns it a market valuation of $22.34M. That closing price of RLMD’s stock is at a discount of -567.16% from its 52-week high price of $4.47 and is indicating a premium of 64.18% from its 52-week low price of $0.24. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.48 million shares which gives us an average trading volume of 1.79 million if we extend that period to 3-months.
For Relmada Therapeutics Inc (RLMD), analysts’ consensus is at an average recommendation of Sell while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Relmada Therapeutics Inc (NASDAQ:RLMD) trade information
Upright in the green during last session for gaining 25.53%, in the last five days RLMD remained trading in the red while hitting it’s week-highest on Thursday, 06/26/25 when the stock touched $0.67 price level, adding 8.83% to its value on the day. Relmada Therapeutics Inc’s shares saw a change of -77.56% in year-to-date performance and have moved -3.83% in past 5-day. Relmada Therapeutics Inc (NASDAQ:RLMD) showed a performance of 1.68% in past 30-days. Number of shares sold short was 0.7 million shares which calculate 0.92 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 90.43% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would drop -198.51% in reaching the projected high whereas dropping to the targeted low would mean a loss of -198.51% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0.68% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 27.17% while estimates for its earnings growth in next 5 years are of 31.28%.
Relmada Therapeutics Inc (NASDAQ:RLMD)’s Major holders
Insiders are in possession of 17.03% of company’s total shares while institution are holding 33.39 percent of that, with stock having share float percentage of 40.24%. Investors also watch the number of corporate investors in a company very closely, which is 33.39% institutions for Relmada Therapeutics Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at RLMD for having 1.26 million shares of worth $3.77 million. And as of 2024-06-30, it was holding 16.6593 of the company’s outstanding shares.
The second largest institutional holder is DEEP TRACK CAPITAL, LP, which was holding about 1.23 million shares on 2024-06-30. The number of shares represents firm’s hold over 16.3686 of outstanding shares, having a total worth of $3.7 million.
